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Objectives: Clostridium difficile infection (CDI) is a global healthcare problem. Recent evidence suggests that the
availability of iron may be important for C. difficile growth. This study evaluated the comparative effects of iron-
depleted (1% Fe3+ saturated) bovine apo-lactoferrin (apo-bLf) and iron-saturated (85% Fe3+ saturated) bovine
holo-lactoferrin (holo-bLf) in a human in vitro gut model that simulates CDI.
Methods: Two parallel triple-stage chemostat gutmodels were inoculated with pooled human faeces and spiked
with C. difficile spores (strain 027 210, PCR ribotype 027). Holo- or apo-bLf was instilled (5 mg/mL, once daily) for
35 days. After 7 days, clindamycin was instilled (33.9 mg/L, four times daily) to induce simulated CDI. Indigenous
microflora populations, C. difficile total counts and spores, cytotoxin titres, short chain fatty acid concentrations,
biometal concentrations, lactoferrin concentration and iron content of lactoferrin were monitored daily.
Results: In the apo-bLf model, germination of C. difficile spores occurred 6 days post instillation of clindamycin,
followed by rapid vegetative cell proliferation and detectable toxin production. By contrast, in the holo-bLf model,
only a modest vegetative cell population was observed until 16 days post antibiotic administration. Notably, no
toxin was detected in this model. In separate batch culture experiments, holo-bLf prevented C. difficile vegetative
cell growth and toxin production, whereas apo-bLf and iron alone did not.
Conclusions: Holo-bLf, but not apo-bLf, delayed C. difficile growth and prevented toxin production in a human
gut model of CDI. This inhibitory effect may be iron independent. These observations suggest that bLf in its
iron-saturated state could be used as a novel preventative or treatment strategy for CDI.
Introduction
Clostridium difficile infection (CDI) is a global healthcare problem.
It is the leading cause of hospital-acquired infectious diarrhoea,
causing significant morbidity and societal financial burden.1,2
Recurrent infections and increasing antibiotic resistance have
complicated the treatment of CDI.3 – 5 There is now, therefore,
an urgent need for the development of novel, non-antibiotic-
based therapeutic and preventative strategies. To successfully
sustain an infection, nearly all bacteria, fungi and protozoa require
a continuous supply of host iron, which participates in many
essential metabolic processes.6 Recent in vitro evidence suggests
that the availability and source of iron may be important for
C. difficile growth.7 The development of pharmaceutical agents
that can manipulate microbial access to iron may help prevent
and possibly treat CDI.
Lactoferrin, a multifunctional ferric (Fe3+) iron-binding glyco-
protein found inmilk, in severalmucosal secretions and in second-
ary granules of neutrophils, exhibits bacteriostatic activity due to
its ability to sequester iron, thereby depriving potential pathogens
of this essential nutrient.8 Multiple in vitro and animal studies
show that both human and bovine iron-depleted forms of lacto-
ferrin, which share similar sequence homology, similar three-
dimensional structures and comparable bioactivity, inhibit growth
of enteric bacteria.9 Faecal lactoferrin is a biomarker for intestinal
inflammation.10 Quantitative faecal lactoferrin has been shown
to correlate with the degree of colonic inflammation and disease
severity in inflammatory bowel disease.10 –12 Similarly, faecal
lactoferrin concentration has been shown to be elevated in CDI
patients,13–15 with more recent reports suggesting a positive cor-
relation with disease severity.13–16 However, it is acknowledged
that there is wide variability among patients and that larger
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cohort studies are needed in order to evaluate the potential of
faecal lactoferrin concentration as an objective predictor of poor
outcome in hospitalized patients.15
The aim of this research was to evaluate for the first time the
comparative effects of iron-depleted (1% Fe3+ saturated) bovine
apo-lactoferrin (apo-bLf) and iron-saturated (85% Fe3+ satu-
rated) bovine holo-lactoferrin (holo-bLf) in a human in vitro gut
model predictive of CDI. We hypothesized that apo-bLf (unlike
holo-bLf) would compete with C. difficile for free iron, thus inhibit-
ing C. difficile growth, sporulation and toxin production and so
preventing CDI while having little effect on the indigenous gut
microbiota.
Materials and methods
Triple-stage in vitro human gut model
A validated and clinically reflective triple-stage chemostat model was used
to simulate CDI. The model consists of three water-jacketed (378C) glass
vessels arranged in a weir cascade formation and top fed with a complex
growth media (dilution rate, 13.2 mL/h). The model is primed with a
pooled human faecal emulsion, and each vessel is sparged with nitrogen
to ensure anaerobic conditions and maintained at a gut-reflective pH (ves-
sel 1¼5.5, vessel 2¼6.2, vessel 3¼6.8). The system has been validated
against the intestinal contents of sudden-death victims, and it provides a
close simulation of bacterial activities and composition in different areas
of the colon.
C. difficile strain and spore preparation
C. difficile strain 027 210 (BI/NAP1/PCR ribotype 027/ toxinotype III) was
used. This strain was isolated during a clinical outbreak of CDI at Maine
Medical Center (Portland, ME, USA) and was kindly supplied by Dr Robert
Owens. Spores were initially grown on cefoxitin/cycloserine/egg yolk agar
plus lysozyme (CCEY/L) for 48 h, before being subbed onto Columbia Blood
Agar (40 plates). Following checks for purity, all growth was harvested into
sterile saline (2 mL). An equal volume of ethanol was added to the spore
suspension to kill any vegetative cells. The spore suspensionwas subject to
trypsin digestion and washing, to remove debris, and enumerated on
CCEYL. The spore preparation was diluted in 50% ethanol to achieve
107 cfu/mL.
Preparation of bovine apo- and holo-lactoferrins
Bovine lactoferrin (bLf) was purchased from Morinaga Milk Industry (80%
purity and 10% Fe3+ saturation; Zama, Japan) and stored at 48C.
Apo-lactoferrin (apo-bLf) was prepared by dissolution of lactoferrin pow-
der in Milli-Q water to obtain 50 mg/mL solution and dialysed extensively
against 100 mM citrate buffer (POCH S.A.; Gliwice, Poland), pH 3.5 with
200-fold volume excess of the buffer for 24 h (with three buffer changes),
followed by dialysis against Milli-Q water for 24 h.17 Holo-lactoferrin
(holo-bLf) was prepared by the reaction of 50 mg/mL lactoferrin solution
in 50 mM Tris-(hydroxymethyl) aminomethane (VWR BDH Prolabo; Dublin,
Ireland), 150 mM sodium chloride (POCH S.A., Gliwice, Poland), 25 mM
sodium bicarbonate (pH 7.4; Sigma-Aldrich) with 4-fold molar excess of
ferric nitrate salt over lactoferrin. Buffers and reagents in all experiments
were prepared using Milli-Q water (18 MV). After 1 h of incubation at room
temperature, unbound iron was removed by dialysis against Milli-Q water
for 24 h (with three water changes).17 Both apo- and holo-bLf were freeze
dried and stored at 48C. Iron saturation of apo- and holo-bLf preparations
was calculated based on the A280/A466 ratio according to the calibration
curve presented byMajka et al.17 Prepared apo-bLfwas 1% Fe3+ saturated,
while holo-bLf Fe3+ saturation was 85%.
Experimental design
Two models were run in parallel (Figure 1). Each vessel was primed with
150 mL of faecal emulsion (10% w/v in pre-reduced PBS) prepared
from C. difficile-negative faecal samples from five healthy volunteers
(age .60 years) with no history of antibiotic therapy for .3 months. The
volunteers gave appropriate consent for their samples to be used in this
study. The models were left for 10 days to equilibrate to allow bacterial
populations to reach steady-state (period A). A single aliquot of C. difficile
PCR ribotype 027 spores (107 cfu) was added into vessel 1 of eachmodel
and left for a 7 day C. difficile control period (period B). Lactoferrin instilla-
tion commenced on day 17 and continued for the duration of the experi-
ment. 5 mg/mL apo-bLf was added once daily to model A and 5 mg/mL
holo-bLf was added once daily to model B. After a 7 day lactoferrin control
period (period C), a second aliquot of C. difficile spores was added and clin-
damycin instillation commenced (33.9 mg/L, four times daily for 7 days,
period D). Following clindamycin instillation, the models were monitored
for a further 3 weeks (period E). Gut microflora populations in vessels 2
and 3 were monitored on selective and non-selective agars on the basis
of appearance, colony morphology, microscopy and MALDI-TOF, as previ-
ously described,18 every other day during period A and daily thereafter.
Inoculation
with faecal
slurry
Steady-state
Model A
Model B
17 24 31 51
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(5 mg/mL per day)
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(5 mg/mL per day)
0 10
A B C D
CLI
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E
Day
C. difficile
spores
107 cfu
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Figure 1. Experimental design. A¼steady-state, B¼C. difficile control period, C¼ lactoferrin control period, D¼C. difficile infection and E¼rest stage. CLI,
clindamycin; qds, four times daily.
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C. difficile total viable counts (vegetative cells and spores), spore counts and
toxin titres in all vessels were enumerated daily from period B onwards, as
previously described.18 Briefly, toxin levels were measured by cell cytotox-
icity assay daily following inoculation of C. difficile into the gutmodel. Model
fluid was centrifuged, and the supernatant was subjected to 10-fold dilu-
tion. Diluted supernatant was inoculated onto confluent Vero cells and
incubated, and cells were examined after 24 and 48 h. Samples were con-
sidered positive for C. difficile toxin if cell rounding was observed in 80% of
wells and effects were neutralized by the presence of sordelli antitoxin. If
rounding was observed in the neat sample only, a titre of 1 relative unit
(RU)was assigned; a titre of 2 RUwas assigned if cell roundingwas observed
in neat and 1:10 dilutions and a titre of 4 RU was assigned if cell rounding
was observed in neat, 1:10 and 1:100 dilutions.
Ethics statement
Ethics approval for the collection and use of faecal donations from healthy
adult volunteers was provided by the Leeds Institute of Health Sciences
and Leeds Institute of Genetics, Health and Therapeutics and Leeds
Institute of Molecular Medicine, University of Leeds joint ethics committee
(reference HSLTLM/12/061).
Determination of lactoferrin concentrations
The concentration of lactoferrin in the gut-model fluid was measured
using a bLf ELISA kit (Alpha Diagnostic International, San Antonio, TX,
USA). Representative samples were drawn at 19 pre-selected timepoints
across the different experimental time periods following addition of lacto-
ferrin. A standard curve was prepared with the supplied bLf standards with
concentrations ranging from 4 to 80 ng/mL. The analysed gut-model fluid
samples were diluted 1:100000 in sample diluent buffer and the test was
performed according to the manufacturer’s protocol. ELISA plates were
read using an Infinite 200 Reader (Tecan) plate at 450 nm to determine
lactoferrin concentration.
Estimation of iron saturation in lactoferrin preparations
Lactoferrin saturation was evaluated in the highmolecular fraction of gut-
model fluid samples at 12 separate timepoints. These points again were
chosen as representative timepoints following addition of lactoferrin.
Protein content in test samples before and after lactoferrin application
was analysed by SDS-PAGE. Prior to lactoferrin application, no proteins
were detected in the gut-model fraction; after lactoferrin addition, the
major fraction was lactoferrin. Iron concentration in fractions higher
than 3 kDa was attributed to lactoferrin. To separate lactoferrin bound
iron and free iron, 500 mL test samples were ultrafiltered on Amicon
Ultra-4 Centrifugal Filter Units (Merck Millipore) with molecular weight
cut-off 3 kDa (7500 g, 30 min, 48C). Lactoferrin concentration was ana-
lysed using ELISA in the high molecular fraction, following a 1000000×
dilution of the tested samples with the diluent buffer. Iron content was
analysed after mineralization of 40 mL of test sample with 500 mL of con-
centrated nitric acid (65%, Suprapur) overnight. Iron concentration was
determined in these mineralized samples following dilution with Milli-Q
water to obtain a 5 mL solution using the inductively coupled plasma
optical emission spectroscopy (ICP-OES) technique. The latter was per-
formed with a Plasma 40 PerkinElmer spectrometer. The 57Fe isotope
was used for the quantification of iron content in samples.
Determination of antimicrobial concentrations
Gut-model fluidwas sampled daily fromeach vessel from the start of period
Donwards, and clindamycin concentrationswere determined by large-plate
bioassay. Samples were frozen at 2208C and assayed retrospectively.
Defrosted samples were centrifuged, and the supernatants were filtered
through 0.22 mm syringe filters. Wilkins–Chalgren agar (100 mL) was ster-
ilized byautoclaving, cooled to 508C, inoculatedwith 1 mL Kocuria rhizophila
(ATCC 9341) indicator organism suspension and transferred aseptically into
245×245 mm agar plates. Plates were dried (378C, 10 min) and 25 wells
dug with a 9 mm diameter cork borer. Twenty microlitres of antibiotic cali-
brator or gut-model sample was inoculated into bioassay wells. Bioassay
plates were incubated at 378C overnight. Diameters of each zone of inhib-
ition were measured using callipers accurate to 0.1 mm, and antimicrobial
concentrations were determined by comparison with known antimicrobial
standard concentrations.
Determination of biometal concentrations
Total iron, zinc, copper and manganese biometal content in vessel 3 gut-
model sampleswasmeasured by the application of the ICP-OES technique
using a Plasma 40 PerkinElmer spectrometer. Representative samples
were drawn at 19 timepoints, representing all experimental time periods.
Prior to the determination of biometal content, 100 mL of the tested sam-
ples was incubated overnight with 500 mL of concentrated nitric acid and
subsequently diluted with Milli-Q water to obtain a 5 mL solution. Metal
content in the samples was measured with two repetitions.
Determination of short chain fatty acid (SCFA)
concentrations
SCFA concentrations (mM) of the gut-model fluid samples in vessel 3 were
quantified at 20 representative timepoints spanning the entire experimen-
tal period by GC-MS. Standard solutions of acetic acid, propanoic acid,
butyric acid, isobutyric acid, valeric acid and isovaleric acid were prepared
at different concentrations (100, 200, 400 and 800 mM). Injection was
made in splitless mode with an injection volume of 1 mL. The volatiles
were transferred onto a new Zebron ZB-FFAP column (30 m×0.25 mm
×0.25 mm film thickness; Phenomenex, UK) and chromatogram with
helium as the carrier gas at 18 psi. The GC starting temperature was
608C, held for 1 min and ramped to 1808C at 88C/min. All the compounds
were detected with a DSQ mass spectrometer (Thermo Scientific) in scan
mode, 20–150 mass:charge ratio). Identification of SCFAs was based on
the retention time of standard compounds and with the assistance of
the data library of the National Institute of Standards and Technology.
Lactoferrin batch culture
Aliquots of brain heart infusion (BHI) broth (10 mL) in glass vials were
supplemented with either holo-bLf (50 mg), apo-bLf (50 mg) or iron
(50 mL of stock solution containing 496 mg of FeO4S.7H2O in 10 mL of
H2O) alongside non-supplemented controls. These broths were inoculated
with C. difficile (strain 027 210). One set of broths was inoculated with
100 mL of C. difficile spores (108 cfu/mL) and the other set of broths was
inoculated with 100 mL of an overnight vegetative Schaedler broth culture.
Samples were taken at 24 and 48 h, and total viable counts, spore counts
and toxin titres were enumerated in triplicate (as previously described).
Results
C. difficile total viable counts, spore counts and cytotoxin
As seen in previous gut-model experiments, C. difficile remained
as spores before (period B) and during (period C) clindamycin
instillation in both models (Figure 2). Following the wash-out
of detectable clindamycin activity (4 days into period E), an
increase in total viable counts over spore counts was observed,
indicating a vegetative cell population. In the apo-bLf model, this
germination was followed by rapid vegetative cell proliferation
and toxin production (Figure 2a). However, in the holo-bLf
model, there was only a modest vegetative cell population
(total counts 1 log10 cfu/mL greater than spore counts), with
prolific vegetative growth not occurring until 16 days post
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clindamycin instillation. Notably, no toxin was detected in the
holo-bLf model at any timepoint (Figure 2b).
Gut microflora counts
The effect of clindamycin instillation (period C) on gut microflora
populations was similar in both models and similar to that in
previously described gut-model work (data not shown).18 –21
Bifidobacteria populations decreased 7 log10 cfu/mL, to below
the level of detection, but recovered to steady-state levels by
the end of the experiment. Enterococci populations increased
4 log10 cfu/mL.Minor fluctuationswere observed in other popula-
tions, but population stability returned by the end of the
experiment.
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Figure 2. Planktonic C. difficile populations in vessel 3 of the (a) apo-lactoferrin and (b) holo-lactoferrin models. CD indicates insertion of C. difficile
spores. A–E indicate experimental stages (see the Materials and methods section). This figure appears in colour in the online version of JAC and in
black and white in the print version of JAC.
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Figure 3. Lactoferrin concentration and iron saturation in vessel 3 of the (a) apo-lactoferrin and (b) holo-lactoferrin models. A–E indicate experimental
stages (see the Materials and methods section).
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Lactoferrin and iron-saturation levels
Lower mean concentrations of lactoferrin (1 mg/mL) were
observed in vessel 3 of the apo-bLf model from period C onwards
compared with concentrations in the holo-bLf parallel model
(2 mg/mL rising to a peak of just under 3 mg/mL (Figure 3). These
findings suggest that both forms of lactoferrinmay be subject to pro-
teolytic degradation,with apo-bLf showing greater susceptibility than
holo-bLf. Alternatively, lactoferrinmay be being absorbed on the bac-
terial cell walls or protein precipitation may account for the lower
levels of bLf in bothmodels. The iron content of lactoferrinwas higher
in the iron-laden holo-bLf model rising to a peak of just under 160%
following clindamycin instillation and CDI induction (Figure 3b).
Iron-saturation values of.100% indicate that there ismore iron rela-
tive to accessible iron-binding sites in lactoferrin. These iron ions can
be bound in a non-specific way as trivalent cations.
Total metal concentrations
Total iron concentration was higher in the iron-laden holo-bLf
model, rising to a peak of just under 10 mg/L compared with
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that in the parallel apo-bLf model, in which levels peaked at just
over 1 mg/L (data not shown). No marked differences in the con-
centrations of the other total metals were observed between the
models, in which manganese and zinc concentrations were just
above the limits of detection, unlike that of copper, which fell
below the limit of detection (data not shown).
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Figure 5. C. difficile total viable counts (TVC; in log10 cfu/mL), spore counts (SP; in log10 cfu/mL) and toxin titre (in RU) at 24 and 48 h following inoculation
with (a) vegetative C. difficile and (b) C. difficile spores into non-supplemented BHI (control) or BHI supplemented with apo-lactoferrin (apo-bLf),
holo-lactoferrin (holo-bLf) or iron. Bars represent+SEM.
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SCFA concentrations
Acetic acid, propanoic acid, isobutyric acid, butyric acid, isovaleric
acid and valeric acid were present in varying concentrations in all
samples tested from vessel 3 of each gut model. Both acetic and
butyric acids were the most quantitatively significant SCFAs pro-
duced (Figure 4), followed by propanoic, isovaleric, valeric and iso-
butyric acids. Throughout, concentrations of valeric, isovaleric and
isobutyric acids were very low. Clindamycin-induced disruption of
gut-model-associated microbial communities was accompanied
by a sharp decline in butyric acid production, which recovered in
the rest phase, although recovery in the holo-bLf model was
3 days later and only partial (Figure 4b). In both models, acetic
acid concentration increased following antibiotic administration.
Investigation of the effects of holo-bLf, apo-bLf and
additional iron (iron sulphate) on C. difficile growth,
sporulation and toxin production when cultured using
in vitro batch culture
Iron concentrations in all samples did not vary greatly between 24
and 48 h of incubation. Control and apo-bLf-supplemented broths
contained 1–4 mg/L iron. Holo-bLf-supplemented broths con-
tained 13–19 mg/L iron (similar to the 10 mg/L observed in
the holo-bLf gut model) and the iron-supplemented broths con-
tained 35–38 mg/L iron, exceeding those concentrations
observed in the holo-bLf gut model.
Following inoculation with C. difficile overnight culture, high
levels of vegetative cell growth (difference between total counts
and spore counts) and toxin production were observed in control,
apo-bLf-supplemented and iron-supplemented samples at both
24 and 48 h. However, little vegetative growth and no toxin were
detected in the holo-bLf-supplemented samples (Figure 5a). The
same was true following inoculation with C. difficile spores
(Figure 5b), although toxin detection was delayed in the apo-bLf-
supplemented samples compared with that in the control and
iron-supplemented samples. Interestingly, the iron-supplemented
samples inoculated with an overnight culture contained higher
levels of spores at 48 h than the other samples, although this
increased sporulationwas not observed following initial inoculation
with spores.
The samples inoculated with spores showed delayed toxin pro-
duction compared with that in the samples inoculated in an over-
night culture (4 RU versus 5 RU at 24 h for control samples),
although the same final titre (5 RU) was observed at 48 h. This
observation likely reflects the impact of spore germination,
which is required before vegetative proliferation and toxin produc-
tion can occur. The same delay would not be in place following
inoculation of an overnight culture, as this culture will consist of
a large proportion of vegetative cells.
Discussion
We have investigated for the first time the effects of bLf, a natural
bi-globular iron-binding glycoprotein with potent broad-spectrum
antimicrobial activities,9,22–24 to prevent CDI in vitro. The triple-
stage human gut model has been shown to produce results
that correlate well with clinical observations.25–33 In the present
study, the addition of holo-bLf delayed C. difficile vegetative cell
growth and completely prevented toxin production. In contrast,
C. difficile germination was seen much earlier in the apo-bLf
model and was followed by rapid vegetative cell proliferation
and detectable toxin production. These findings were reproduced
in separate in vitro batch culture experiments. The presence of
holo-bLf prevented vegetative cell proliferation and toxin produc-
tion, whereas apo-bLf did not. Notably, the presence of excess iron
alone did not prevent vegetative cell proliferation and toxin pro-
duction. These additional studies suggest that the antimicrobial/
inhibitory effect of holo-bLf is not likely to relate to iron toxicity.
Furthermore, in comparison with apo-bLf, holo-bLf appeared to
be more resistant to proteolytic degradation. These observations
reflect similar findings in vivo, where iron-saturated bLf is more
resistant to gut digestion.34,35 The exact mechanism or mechan-
isms by which holo-bLf exerts its increased antimicrobial activity
remain elusive, but a possible explanation is that holo-bLf is more
bioavailable (and resistant to degradation and proteolysis) than
apo-bLf. A further possibility is that iron binding to bLf induces
conformational changes that allow it to access the C. difficile
cell wall. Following hydrolysis, positively charged lactoferrin-
derived peptides (lactoferricin H and B) can interact with the nega-
tively charged teichoic acid layer that surrounds the cytoplasmic
membrane of Gram-positive bacteria.36 Incorporation of lactofer-
ricin into the bacterial cytoplasm has been shown to inhibit DNA,
RNA and protein synthesis.37–39Whether the generation of lacto-
ferricin might account for the activity of bLf against C. difficile
growth and toxin production remains to be demonstrated.
Alternatively, protein precipitation may account for the low levels
of bLf in both models. The issue concerning protein precipitation
was not explored, because of the complicated model set-up
required. However, normally only a small fraction of proteins
undergo precipitation due to lack of optimal environmental condi-
tions or as a result of changes induced by components of
the media. In general, gut microflora components were affected
to a largely similar degree by clindamycin in both models.
Bifidobacterium spp. were most clearly inhibited; reduced viable
counts of Bifidobacterium spp. correlated with C. difficile spore
germination and proliferation in all prior gut-model experiments
with clindamycin.32,33 Furthermore, also reflecting previous
observations,40 acetic, butyric and propanoic acid were the
major SCFAs detected quantitatively, with smaller contributions
from isobutyric, isovaleric and valeric acids. Clindamycin-induced
disruption of gut-associated microbial communities was accom-
panied by a marked depletion of butyric acid SCFA levels. Similar
results have been observed by Rea et al.,41 who reported that
C. difficile-positive patients had a decrease in Bacteroides,
Prevotella and Bifidobacteria and an increase in members of the
Lactobacillaceae and Enterobacteriaceae families. Moreover, the
relative abundance of butyric-acid-producing bacteria was signifi-
cantly lower in patients with CDI and nosocomial diarrhoea.42
These findings suggest that the fermentation patterns or compos-
ition of SCFAs are closely related to bacterial composition and that
variations in the bacterial flora and thus microbiota-derived
metabolites may be more important in determining C. difficile
susceptibility in vivo. It follows that as Bifidobacteria are normally
present in high numbers in the human gut and are implicated in
preventing establishment of pathogenic bacteria like C. difficile,43
their depletion may induce reduced production of SCFAs such as
butyric acid, which has an important trophic effect on colonic epi-
thelial cells.44 It is also possible that other compositional changes
in specific butyrogenic bacterial species including Clostridium
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leptum, Roseburia spp., Faecalibacterium prausnitzii and Coprococcus
spp. belonging to both the Firmicutes and Bacteroidetes phyla45may
have caused butyric acid depletion, particularly aswedid not employ
culture-independent high-throughput sequencing to dissect the role
of antibiotics and lactoferrin on gut microbiota composition. Taken
together, these studies suggest that individuals with sufficient levels
of intestinal SCFAs, specifically butyric acid, may be less susceptible
to CDI. Interestingly, commensalmicrobe-derived butyrate has been
shown to induce the differentiation of colonic Foxp3-expressing
regulatory T cells, which have a central role in the suppression of
inflammatory and allergic responses.46 Mice fed a starch-rich
butyrate-supplemented dietweremore protected against the devel-
opment of colitis comparedwith those fed a starch-rich diet without
supplementation. Butyrate appeared to up-regulate the transcrip-
tion of genes involved in differentiation of regulatory T cells in the
gut by enhancing H3 acetylation.46
From a translational perspective, bLf has a proven good
safety profile in pre-clinical animal studies and human clinical
trials.34,47–49 The European Food Safety Authority, the FDA (USA)
and the Therapeutic Goods Administration (Australia) have
approved bLf for use in food, sports medicine and nutritional
products. Oral delivery is the most common method for bLf
administration. However, an appropriate delivery system is
required to circumvent proteolytic digestion in the stomach and
intestines and thus improve absorption and bioavailability within
the gastrointestinal tract. Particulate carrier systems have been
identified to protect bLf against proteolysis via encapsulation
using pectin- and chitosan-modified liposomes and solid lipid
particles.50 Nanoformulated iron-saturated bLf has been success-
fully tested for its antimicrobial efficacy. Orally fed, alginate gel-
encapsulated ceramic nanocarriers loaded with iron-saturated
bLf alone were more effective than ciprofloxacin therapy in
salmonella-infected mice.51
The present study had a number of limitations. Firstly, given the
nature, labour intensiveness and expense of the current experi-
mental design, it was not possible to evaluate the effects of mul-
tiple strains of C. difficile, dose-ranging bLf concentrations or
differing iron-saturation states of the bLf. We generated bLf iron-
saturation states that represented each end of the spectrum
(apo- and holo-forms), as such an approach is commonly cited.
Although we tested only one concentration of bLf (5 mg/mL),
we chose this concentration in line with previous randomized con-
trol trial data demonstrating its efficacy in significantly reducing
the occurrence of antibiotic-associated diarrhoea in long-term
care patients compared with placebo.52 Moreover, given the
respective working volume of vessel 1 (280 mL), the total amount
of bLf added per day of the experiment was 1400 mg. This dosage
falls at the midpoint recommended by health and food compan-
ies for human consumption, which is,3 g of lactoferrin per day.53
It is largely unknown whether lactoferrin maintains its integrity
and to what degree, and at what time it is hydrolysed into pep-
tides in the human gastrointestinal tract. Moreover, the degrad-
ation of lactoferrin and the formation of bioactive peptides is
highly dependent on individual variation in intraluminal compos-
ition.54 Factors such as gastric pH, age of the consumer and enzy-
me:substrate ratios seem to be important.55 Troost et al.33
showed that a major proportion (60%–80%) of bLf administered
in a high dosage (15 mg/mL) survived passage through the stom-
ach in adults. Therefore, we anticipate that it may be necessary to
use higher oral dosages of bLf in vivo than those used in the gut
model. It will thus be important to consider employing strategies
to overcome insufficient bioavailability of lactoferrin through, for
example, the use of pH sensitive polymer-coated drug delivery
systems.56 For reasons cited earlier, wewere also unable to evalu-
ate the separate role of iron in the gutmodel set-up. Nevertheless,
we did undertake comparative studies investigating the effects of
control, apo-bLf, holo-bLf and excess iron in lactoferrin in vitro
batch culture experiments. Furthermore, we did not investigate
the stability of bLf throughmonitoring the derivatization products,
including peptides such as lactoferricin. Finally, although this
model is well validated and clinically reflective with regards to
intestinal microbiota populations, it is limited in that it does not
simulate host factors such as the immune response.57
Future investigations into the roles of apo-bLf, native bLf and
holo-bLf in vivo are of clear importance in order to establish the
role of bLf and its iron-binding status for the prevention and treat-
ment of CDI. Whether treatment with bLf renders intestinal epi-
thelia less susceptible to C. difficile toxins or microbial invasion
remains to be investigated. Interestingly, bLf is effective in inhibit-
ing cholera toxin-induced fluid accumulation in mice via abolition
of toxin–receptor interaction.58 In future animal studies, we plan
to perform bLf dose titration experiments and to evaluate the
effects of alternative modes of drug delivery (for example, inter-
gastric gavage, buccal deposition, intra-muscular). Follow-up
work is also planned to test a range of lactoferrin saturation states
in order to establish an optimal saturation level (initially 1%,
10%–15%, 40%–50% and .85%). In addition, we intend to
test the effects of excess iron (iron oxide and iron oxide nanopar-
ticles), liposomal-encapsulated iron-saturated bLf and purified
lactoferricin in a murine model of CDI. Using this approach, the
immunomodulatory, anti-inflammatory and cell-proliferative
activities of lactoferrins59,60mayalso be evaluated at themucosal
level. Laboratory studies will also be conducted to ascertain if the
antimicrobial activity of bLf exerts beneficial effects on the struc-
ture and function of themurine intestinalmicrobiota. If our in vitro
gut model observations are subsequently validated in the murine
setting and are informative with regards to the optimal dosing
strategyand deliverymodality, wewould aim to undertake clinical
trials in the near future.
In conclusion, iron-enriched bLf is a comparatively inexpensive
product that has proven to exhibit no adverse toxicity.61 The
aforementioned panoply of features noted in this novel study indi-
cate that holo-bLf might be a promising and attractive supple-
ment to add to standard antimicrobial regimens against
C. difficile and/or it could be used alone to potentially delay or
inhibit C. difficile growth and toxin production. In addition, replen-
ishing butyrogenic bacteria to allow in situ generation of butyric
acid or other inhibitory compounds in the gut lumen may offer
another novel therapeutic strategy for the treatment and preven-
tion of CDI.
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